IMRX net incomeQ3 2026-$24.19M
IMRX net income was -$24.19M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.96M a year earlier. For the full fiscal 2025 it was -$56.02M, compared with -$61.04M in fiscal 2024.
Immuneering Corporation (IMRX) financials
For the twelve months ended Sep 30, 2026, Immuneering Corporation reported -$66.50M of net income.
- Net income, TTM
- -$66.50M
- Free cash flow, TTM
- -$61.81M
- Cash
- $58.23M
- Market cap
- $236.4M
FY2020FY2023
FY2020FY2025
FY2020FY2025
IMRX revenue and earnings growth
IMRX EPSQ3 2026-$0.37
IMRX diluted EPS was -$0.37 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$1.27.
IMRX free cash flowQ3 2026-$16.80M
IMRX free cash flow was -$16.80M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$11.98M a year earlier. For the full fiscal 2025 it was -$45.49M, compared with -$55.08M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $317.0K | $2.08M | $2.31M |
| Cost of revenue | - | - | $0 | $158.1K | $1.15M | $1.28M |
| Gross profit | - | - | $0 | $158.8K | $926.9K | $1.03M |
| Research and development | $42.05M | $47.96M | $41.62M | $36.27M | $26.54M | $15.00M |
| Selling, general and admin | $17.30M | $16.08M | $16.76M | $15.61M | $8.27M | $3.11M |
| Operating income | -$59.38M | -$64.07M | -$58.41M | -$51.74M | -$33.89M | -$17.08M |
| Pre-tax income | - | - | - | -$50.51M | -$33.84M | -$17.04M |
| Income tax | $0 | - | - | - | -$307.5K | - |
| Net income | -$56.02M | -$61.04M | -$53.47M | -$50.51M | -$33.54M | -$17.04M |
| EPS, basic | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 | -$3.44 |
| EPS, diluted | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 | -$3.44 |
| Diluted shares | 44.0M | 30.0M | 28.4M | 26.4M | 13.6M | 5.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $128.65M | $36.14M | $59.41M | $72.64M | $74.89M | $37.09M |
| Short-term investments | - | - | - | $32.89M | $74.31M | - |
| Receivables | - | - | $0 | $12.4K | $246.0K | $500.1K |
| Current assets | $176.25M | $39.59M | $89.08M | $108.75M | $152.33M | $37.73M |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.69M | $6.70M | - |
| Total assets | $231.99M | $52.71M | $102.58M | $122.37M | $166.70M | $38.42M |
| Current liabilities | $10.07M | $7.50M | $7.85M | $8.05M | $5.63M | $2.26M |
| Total liabilities | $13.50M | $11.33M | $12.01M | $12.52M | $10.72M | $2.80M |
| Shareholders' equity | $218.48M | $41.39M | $90.58M | $109.85M | $155.98M | -$22.48M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$45.34M | -$55.00M | -$48.97M | -$44.10M | -$30.85M | -$14.62M |
| Capital expenditures | $142.2K | $84.9K | $342.7K | $742.5K | $60.8K | $53.4K |
| Free cash flow | -$45.49M | -$55.08M | -$49.31M | -$44.84M | -$30.91M | -$14.67M |
| Investing cash flow | -$88.74M | $26.43M | $7.30M | $41.83M | -$75.62M | -$53.4K |
| Financing cash flow | $226.58M | $5.30M | $28.44M | $19.0K | $144.26M | $37.98M |
| Stock-based compensation | $6.31M | $6.50M | $5.73M | $4.06M | $1.80M | $1.09M |
| Depreciation and amortization | $324.5K | $355.8K | $322.8K | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -100.0% | -84.8% | -10.0% | - |
| Gross margin | - | - | - | 50.1% | 44.6% | 44.6% |
| Operating margin | - | - | - | -16325.8% | -1629.2% | -739.0% |
| Net margin | - | - | - | -15937.3% | -1612.3% | -737.2% |
| Free cash flow margin | - | - | - | -14148.4% | -1486.2% | -634.8% |
| Return on equity | -25.6% | -147.5% | -59.0% | -46.0% | -21.5% | - |
| Return on assets | -24.2% | -115.8% | -52.1% | -41.3% | -20.1% | -44.3% |
| Current ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 | 16.73 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Cost of revenue | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Gross profit | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Research and development | $20.72M | $14.00M | $10.65M | $9.25M | $10.87M | $10.45M | $11.47M | $14.86M | $11.25M | $10.65M | $11.20M | $11.91M |
| Selling, general and admin | $5.06M | $5.00M | $4.68M | $4.49M | $4.51M | $4.30M | $4.01M | $3.69M | $4.01M | $4.25M | $4.12M | $4.38M |
| Operating income | -$25.79M | -$19.00M | -$15.34M | -$13.75M | -$15.38M | -$14.76M | -$15.48M | -$18.56M | -$15.27M | -$14.91M | -$15.33M | -$16.30M |
| Net income | -$24.19M | -$17.27M | -$13.46M | -$11.58M | -$14.96M | -$14.43M | -$15.05M | -$18.05M | -$14.60M | -$14.08M | -$14.31M | -$15.08M |
| EPS, basic | -$0.37 | -$0.27 | -$0.21 | - | -$0.38 | -$0.40 | -$0.42 | -$0.59 | -$0.49 | -$0.47 | -$0.49 | -$0.51 |
| EPS, diluted | -$0.37 | -$0.27 | -$0.21 | - | -$0.38 | -$0.40 | -$0.42 | -$0.59 | -$0.49 | -$0.47 | -$0.49 | -$0.51 |
| Diluted shares | 64.7M | 64.7M | 64.7M | - | 39.7M | 36.0M | 35.5M | - | 29.8M | 29.7M | 29.4M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $58.23M | $41.32M | $47.32M | $128.65M | $227.56M | $26.36M | $35.87M | $36.14M | $45.21M | $59.73M | $66.29M | $59.41M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Current assets | $150.71M | $157.99M | $161.41M | $176.25M | $229.10M | $27.73M | $38.21M | $39.59M | $55.26M | $63.69M | $74.45M | $89.08M |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M |
| Total assets | $182.56M | $202.06M | $214.81M | $231.99M | $241.06M | $40.06M | $50.68M | $52.71M | $68.56M | $77.09M | $87.98M | $102.58M |
| Current liabilities | $10.79M | $8.12M | $4.97M | $10.07M | $9.55M | $7.49M | $5.11M | $7.50M | $6.92M | $6.78M | $5.18M | $7.85M |
| Total liabilities | $13.88M | $11.32M | $8.29M | $13.50M | $13.08M | $11.12M | $8.84M | $11.33M | $10.84M | $10.78M | $9.26M | $12.01M |
| Shareholders' equity | $168.68M | $190.74M | $206.52M | $218.48M | $227.98M | $28.94M | $41.84M | $41.39M | $57.72M | $66.31M | $78.72M | $90.58M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.79M | -$16.50M | -$18.43M | -$9.84M | -$11.98M | -$9.45M | -$14.08M | -$14.51M | -$13.47M | -$11.53M | -$15.49M | -$11.78M |
| Capital expenditures | $15.2K | $27.4K | $79.9K | $123.9K | $7.3K | $2.1K | $8.9K | $9.4K | $5.3K | $32.8K | $37.5K | $170.9K |
| Free cash flow | -$16.80M | -$16.53M | -$18.51M | -$9.96M | -$11.98M | -$9.45M | -$14.09M | -$14.52M | -$13.48M | -$11.56M | -$15.53M | -$11.95M |
| Investing cash flow | $33.47M | $10.48M | -$63.07M | -$88.72M | -$7.3K | -$2.1K | -$8.9K | $5.49M | -$5.42M | $4.97M | $21.39M | $3.13M |
| Financing cash flow | $220.2K | $24.6K | $180.8K | -$357.5K | $213.19M | -$62.0K | $13.81M | -$41.0K | $4.36M | $0 | $979.9K | $7.8K |
| Stock-based compensation | $2.06M | $1.63M | $1.64M | $1.64M | $1.46M | $1.52M | $1.69M | $1.72M | $1.64M | $1.66M | $1.47M | $1.64M |
| Depreciation and amortization | $86.1K | $84.5K | $81.4K | $75.9K | $78.8K | $84.5K | $85.3K | $86.1K | $88.9K | $90.5K | $90.2K | $89.8K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | - | -100.0% |
| Current ratio | 13.97 | 19.47 | 32.45 | 17.50 | 24.00 | 3.70 | 7.48 | 5.28 | 7.99 | 9.39 | 14.38 | 11.35 |
Source: XBRL data Immuneering Corporation files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
IMRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IMRX | - | - | -$66.50M | - | $236.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
IMRX FAQ
5 questionsIs IMRX profitable?
No. Immuneering Corporation reported a net loss of $66.50M for the twelve months ended Sep 30, 2026.How much cash and debt does IMRX have?
Immuneering Corporation reported $58.23M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is IMRX free cash flow?
Immuneering Corporation generated -$61.81M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$61.56M less capital expenditures.When did IMRX last report financial results?
The latest statements here come from Immuneering Corporation's 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.Where does this IMRX financial data come from?
Quantisnow builds these statements from the structured XBRL data Immuneering Corporation files with the SEC. It is provided for information only and is not investment advice.